Key Highlights
- Revenue for the fiscal second quarter ended September 30, 2026 rose 28% to USD 7.174 million from USD 5.604 million, with U.S. Revenue up 93% to USD 2.796 million.
- The net loss narrowed to USD 66,000, or USD 0.01 per share, from USD 534,000, or USD 0.32 per share, though the weighted share count rose to 4.909 million from 1.646 million.
- Gross profit increased 32% to USD 2.807 million, a Margin of 39% against 38%, which the filing credited to Manufacturing process improvements and customer mix.
- Cash and cash equivalents were USD 4.609 million at September 30, 2026, up from USD 2.399 million at March 31, 2026, after USD 4.275 million of net proceeds from stock sales since October 1, 2025.
U.S. Demand Drives a 28% Revenue Increase
Sonoma Pharmaceuticals filed its Quarterly Report for the fiscal second quarter of 2027, covering the three months ended September 30, 2026, on November 10, 2026. Revenue was USD 7.174 million, with the United States contributing USD 2.796 million, up 93% on higher product demand. Europe was flat at USD 2.148 million, Asia fell 24% to USD 0.801 million on order timing, and Latin America rose 57% to USD 0.835 million. For the six months, revenue was USD 13.580 million, up 41%, with U.S. sales more than doubling, which the filing linked to new and existing distributors. Management said Asian and Rest of World revenue tends to swing because customers place larger orders less often to benefit from quantity discounts and lower shipping costs, so single-quarter regional moves can overstate or understate demand.
How a Small Loss Emerged From Higher Gross Profit
Sonoma Pharmaceuticals (NASDAQ:SNOA) develops and produces stabilized hypochlorous acid products used in wound care, eye care, dermatology, podiatry, animal health and surface disinfection, sold in more than 55 countries, largely through distribution partners. Gross Profit gains outweighed higher spending. Research and Development fell 18% to USD 0.469 million, while selling, general and administrative expense rose 9% to USD 2.048 million on salary increases in Mexico. An income tax expense of USD 0.448 million, against a USD 0.197 million benefit, offset part of the improvement. The six-month net loss was USD 0.396 million, against USD 1.775 million. Cost of revenues was 61% of revenue, down from 62%.
Cash Position, Share Issuance and Remaining Risks
Operating activities used USD 1.385 million of cash over six months, while financing added USD 3.686 million. Working Capital stood at USD 10.928 million, and the accumulated Deficit was USD 201.4 million. Management believes existing cash and offering proceeds should fund operating needs for at least twelve months, but the company has historically relied on selling equity, which dilutes holders. Risks listed include dependence on third-party distributors, regulatory approvals, tariffs and currency swings. As a small company funded by share sales, its quoted price can move sharply on few trades, and such moves can reverse.
Where Things Stand
The loss shrank because sales grew faster than costs. Sonoma Pharmaceuticals (NASDAQ:SNOA) lifted revenue 28% and gross profit 32% while operating expenses rose more slowly, leaving a net loss of USD 66,000 after a tax charge. It is close to break-even, not yet profitable, and the per-share comparison is complicated by a share count that has grown. Next markers are whether U.S. distributor demand holds, how lumpy Asian orders land, the next fiscal quarter's result and any further Equity raises. No guidance appeared in the material reviewed.






Please wait processing your request...